Form 4: Akero Therapeutics CEO Exercises Options and Sells Shares Under 10b5-1 Plan

Akero Therapeutics CEO Andrew Cheng exercised stock options and sold shares on December 2, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Akero Therapeutics CEO Andrew Cheng exercised 25,000 stock options at a price of $21.10 per share on December 2, 2024.
• Following the exercise, Mr. Cheng sold 25,000 shares of common stock at a weighted-average price of $32.09 per share.
• The sales were executed under a pre-existing Rule 10b5-1 trading plan adopted on May 25, 2023.
• The shares were sold in multiple transactions with prices ranging from $31.59 to $32.54.
• After these transactions, Mr. Cheng directly owns 605,417 shares of Akero Therapeutics common stock and 111,029 vested stock options.

Sentiment

Score: 6

Explanation: The document reflects routine transactions by a company executive under a pre-arranged plan. While the sale of shares could be perceived negatively, the use of a 10b5-1 plan mitigates this concern. The sentiment is neutral to slightly positive as it indicates the executive is exercising vested options.

Risks

• The sale of shares by the CEO could be perceived negatively by some investors, although it was conducted under a pre-arranged trading plan.

Industry Context

Transactions of this nature are common for executives of publicly traded companies, especially those with stock-based compensation. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies like Akero Therapeutics, similar to executives at companies such as Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX), which also operate in the biotech space.
• The exercise of stock options and subsequent sale of shares is a typical form of compensation for executives, and the reported prices are within the expected range for such transactions.
• The volume of shares sold is not unusual for an executive exercising options, and the disclosure is consistent with SEC regulations for insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as the sale of shares by the CEO could slightly increase the supply of shares in the market.

Key Dates

Keywords

Akero Therapeutics, Andrew Cheng, stock options, share sale, Rule 10b5-1, insider trading, executive compensation